CARISOPRODOL (kar-eye-soe-proe'dole) Rela, Soma Classifications: autonomic nervous system agent; skeletal muscle relaxant: central-acting Prototype: Cyclobenzaprine Pregnancy Category: C
|
350 mg tablets
Propanediol derivative carbamate with central depressant action pharmacologically related to meprobamate. Precise action mechanism
of CNS depression is not clear. Skeletal muscle relaxant effect, unlike that of neuromuscular blocking agents, appears to
be due to sedative action. Voluntary motor function is not lost, but there may be slight reduction in muscle tone leading
to relief of pain and discomfort of muscle spasm.
Effective spasmolytic and reduces pain associated with acute musculoskeletal disorders.
Skeletal muscle spasm, stiffness, and pain in a variety of musculoskeletal disorders and to relieve spasticity and rigidity
in cerebral palsy.
Hypersensitivity to carisoprodol and related compounds (e.g., meprobamate, tybamate); acute intermittent porphyria; children
<5 y; pregnancy (category C), lactation.
Impaired liver or kidney function, addiction-prone individuals.
Muscle Spasm Adult: PO 350 mg t.i.d. Child: PO
>5 y, 25 mg/kg/d in 4 divided doses
|
Oral
- Give with food, as needed, to reduce GI symptoms. Last dose should be taken at bedtime.
- Store in tightly closed container.
Body as a Whole: Eosinophilia, asthma, fever, anaphylactic shock. CV: Tachycardia, postural hypotension, facial flushing. GI: Nausea, vomiting, hiccups. CNS:
Drowsiness, dizziness, vertigo, ataxia, tremor, headache, irritability, depressive reactions, syncope, insomnia. Skin: Skin rash, erythema multiforme, pruritus.
Drug:
Alcohol,
cns depressants potentiate CNS effects.
Onset: 30 min. Duration: 46 h. Distribution: Crosses placenta. Metabolism: Metabolized in liver. Elimination: Excreted by kidneys; excreted in breast milk (24 times the plasma concentrations). Half-Life: 8 h.
Assessment & Drug Effects
- Monitor for allergic or idiosyncratic reactions that generally occur from the first to the fourth dose in patients taking
the drug for the first time. Symptoms usually subside after several hours; they are treated by supportive and symptomatic
measures.
Patient & Family Education
- Avoid driving and other potentially hazardous activities until response to the drug has been evaluated. Drowsiness is a common
side effect and may require reduction in dosage.
- Report to physician if symptoms of dizziness and faintness persist. Symptoms may be controlled by making position changes
slowly and in stages.
- Do not take alcohol or other CNS depressants (effects may be additive) unless otherwise directed by physician.
- Discontinue drug and notify physician if skin rash, diplopia, dizziness, or other unusual signs or symptoms appear.
- Do not breast feed while taking this drug.